Physician profile
Michael Eisenhauer
NPI 1821064510
$45,905.52
in general payments reported to CMS, 2019-2025
38 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,445 · 2020: $718 · 2021: $1,062 · 2022: $18K · 2023: $13K · 2024: $9,337 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $9,401 · Food and Beverage: $2,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,900.00 |
| Travel and Lodging | $9,400.50 |
| Food and Beverage | $2,443.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $40,218.89 | 2022-2025 | Artis Icono Floor |
| Janssen Pharmaceuticals, INC | $666.86 | 2019-2023 | Xarelto |
| Amgen INC. | $657.96 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $643.52 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $569.30 | 2019-2024 | Camzyos, Eliquis |
| Abbott Laboratories | $465.32 | 2019-2023 | Optis |
| Merck Sharp & Dohme LLC | $424.22 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $318.47 | 2019-2023 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $225.43 | 2021-2023 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $224.12 | 2019 | |
| Biotronik INC. | $219.95 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.50 | 2019-2023 | Lifevest |
| Pfizer INC. | $169.08 | 2020-2024 | |
| Esperion Therapeutics, INC. | $145.26 | 2021 | |
| Chiesi USA, INC. | $93.71 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $78.76 | 2019 | |
| Lundbeck LLC | $55.36 | 2019 | |
| Medtronic Vascular, INC. | $49.86 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.00 | 2019-2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $42.47 | 2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $37.59 | 2023-2024 | Amvuttra |
| Genzyme Corporation | $34.63 | 2022-2023 | |
| Philips North America LLC | $29.20 | 2019 | |
| Terumo Medical Corporation | $28.73 | 2022 | |
| Edwards Lifesciences Corporation | $28.23 | 2020 | |
| Heartflow, INC. | $27.75 | 2022 | |
| Medtronic, INC. | $24.77 | 2022 | |
| Abiomed | $22.06 | 2024 | Impella |
| Ge Healthcare | $18.81 | 2021 | |
| Getinge USA Sales, LLC | $18.62 | 2019 | |
| Daiichi Sankyo INC. | $18.53 | 2024 | Injectafer |
| Lemaitre Vascular, INC. | $18.42 | 2021 | |
| Lantheus Medical Imaging, INC. | $17.35 | 2019 | |
| Shockwave Medical, INC | $16.06 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $15.23 | 2024 | Arcalyst |
| Boston Scientific Corporation | $15.01 | 2023 | |
| Cardiovascular Systems INC. | $14.99 | 2021 | |
| W. L. Gore & Associates, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eisenhauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.